ACA
AMAM

Apis Capital Advisors’s Ambrx Biopharma Inc AMAM Stock Holding History

Apis Capital Advisors’s Portfolio AMAM Stock Details AMAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-34,000
Closed -$391K – 35
2023
Q3 		$391K Hold
34,000
– – 0.51% 18
2023
Q2 		$560K Buy
+34,000
New +$428K 0.56% 26

Other funds holding AMAM

DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Apis Capital Advisors's AMAM Position: Q4 2023 in Review

Apis Capital Advisors sold out of Ambrx Biopharma Inc (AMAM) in Q4 2023, closing a stake of 34,000 shares — an estimated $391K sold.

Apis Capital Advisors first reported a position in AMAM in Q2 2023 and held it in 2 quarters. The position peaked at $560K in Q2 2023. 68 funds tracked by Wall St. Rank hold AMAM as of Q4 2023.

  • Apis Capital Advisors reported no remaining Ambrx Biopharma Inc position as of Q4 2023 after selling out during the quarter.
  • Apis Capital Advisors sold 34,000 Ambrx Biopharma Inc shares in Q4 2023, an estimated $391K.
  • Apis Capital Advisors first reported a position in Ambrx Biopharma Inc in Q2 2023 and held it in 2 quarters.
  • Apis Capital Advisors's Ambrx Biopharma Inc position peaked at $560K in Q2 2023.
  • 68 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q4 2023.

Based on Apis Capital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.